<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01424540</url>
  </required_header>
  <id_info>
    <org_study_id>115535</org_study_id>
    <nct_id>NCT01424540</nct_id>
  </id_info>
  <brief_title>Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805</brief_title>
  <official_title>A Randomized, Double Blind, Single Dose, Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, two part, double-blind, crossover study in healthy adult&#xD;
      subjects to assess the effect of a single dose of GSK2336805 150mg on cardiac function&#xD;
      comparing with placebo using echocardiography as a primary assessment modality&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2011</start_date>
  <completion_date type="Actual">October 3, 2011</completion_date>
  <primary_completion_date type="Actual">October 3, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with a change in ejection fraction greater than 10 percent</measure>
    <time_frame>10 hours</time_frame>
    <description>Echocardiographic measures of contractility</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with electrocardiogram (ECG) parameters out of range</measure>
    <time_frame>3 hours</time_frame>
    <description>Cardiovascular measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with vital signs out of range</measure>
    <time_frame>24 hours</time_frame>
    <description>Cardiovascular measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>24 hours</time_frame>
    <description>tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects using concurrent medication</measure>
    <time_frame>24 hours</time_frame>
    <description>Concomitant medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with laboratory values out of range</measure>
    <time_frame>24 hours</time_frame>
    <description>Labs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (0-24)</measure>
    <time_frame>24 hours</time_frame>
    <description>PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>24 hours</time_frame>
    <description>PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal phase half-life</measure>
    <time_frame>24 hours</time_frame>
    <description>PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lag time before observation of drug concentrations in sampled matrix</measure>
    <time_frame>24 hours</time_frame>
    <description>PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of occurrence of Cmax</measure>
    <time_frame>24 hours</time_frame>
    <description>PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at 24 hours</measure>
    <time_frame>24 hours</time_frame>
    <description>PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between concentration and various safety parameters</measure>
    <time_frame>24 hours</time_frame>
    <description>Safety, PK</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-type natriuretic peptide (BNP) lab result</measure>
    <time_frame>24 hours</time_frame>
    <description>Cardiac biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Troponin lab results</measure>
    <time_frame>24 hours</time_frame>
    <description>Cardiac biomarkers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK2336805 150mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>GSK2336805 Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2336805 150mg</intervention_name>
    <description>Single Dose</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single Dose</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), alkaline phosphatase&#xD;
             and bilirubin less than or equal to 1.5xUpper Limit of Normal (ULN).&#xD;
&#xD;
          -  Healthy as determined by a responsible and experienced physician, based on a medical&#xD;
             evaluation including [medical history, physical examination, laboratory tests and&#xD;
             cardiac monitoring. A subject with a clinical abnormality or laboratory parameters&#xD;
             outside the reference range for the population being studied may be included at the&#xD;
             discretion of the Investigator only if the finding is unlikely to introduce additional&#xD;
             risk factors and will not interfere with the study procedures.&#xD;
&#xD;
          -  Male or female between 18 and 65 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  A female subject is eligible to participate if she is of: Non-childbearing potential&#xD;
             defined as pre-menopausal females with a documented tubal ligation, oophorectomy, or&#xD;
             hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea.&#xD;
&#xD;
        Male subjects with female partners of child-bearing potential must agree to use one of the&#xD;
        contraception methods listed in the protocol. This criterion must be followed from the time&#xD;
        of the first dose of study medication until the follow up visit.&#xD;
&#xD;
          -  Body weight greater than or equal to 50 kilogram (kg) for men and 45 kg for women.&#xD;
             Body mass index (BMI) between 18.5-30 inclusive will be allowed.&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
          -  Subject has demonstrated an adequate echocardiographic window.&#xD;
&#xD;
          -  QTcB less than 450 milliseconds (msec).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A positive pre-study Hepatitis B surface antigen,positive Hepatitis C antibody, or a&#xD;
             positive test for HIV antibody result within 3 months of screening.&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  A positive pre-study drug/alcohol screen.&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study.&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer).&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements (including St John's Wort) within 7 days (or 14 days if the drug is a&#xD;
             potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first&#xD;
             dose of study medication, unless in the opinion of the Investigator and GSK Medical&#xD;
             Monitor the medication will not interfere with the study procedures or compromise&#xD;
             subject safety.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator or GSK&#xD;
             Medical Monitor, contraindicates their participation.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 mililiters within a 56 day period.&#xD;
&#xD;
          -  Pregnant females as determined by positive [serum or urine] hCG test at screening or&#xD;
             prior to dosing.&#xD;
&#xD;
          -  Lactating females.&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
&#xD;
          -  Subject is mentally or legally incapacitated.&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.&#xD;
&#xD;
          -  Subjects who have asthma or a history of asthma.&#xD;
&#xD;
          -  Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or&#xD;
             nicotine-containing products within 6 months prior to screening.&#xD;
&#xD;
          -  Consumption of red wine, seville oranges, grapefruit or grapefruit juice [and/or&#xD;
             pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices] from 7 days prior&#xD;
             to the first dose of study medication.&#xD;
&#xD;
          -  Left ventricular ejection fraction less than 55% at screening.&#xD;
&#xD;
          -  The subject's systolic blood pressure is outside the range of 90-140, or diastolic&#xD;
             blood pressure is outside the range of 45-90 or heart rate is outside the range of&#xD;
             50-100beats per minute for female subjects or 45-100 beats per minute for male&#xD;
             subjects.&#xD;
&#xD;
          -  Exclusion criteria for screening ECG (a single repeat is allowed for eligibility&#xD;
             determination):&#xD;
&#xD;
        Males-Heart rate less than 45 and greater than 100 beats per minute (bpm). Females-Heart&#xD;
        rate less than 50 and greater than 100 bpm Evidence of previous myocardial infarction (Does&#xD;
        not include ST segment changes associated with repolarization).&#xD;
&#xD;
        Any conduction abnormality (including but not specific to left or right complete bundle&#xD;
        branch block, AV block [2nd degree or higher], Wolf Parkinson White [WPW] syndrome). Sinus&#xD;
        Pauses greater than 3 seconds. Any significant arrhythmia which, in the opinion of the&#xD;
        principal investigator and GSK medical monitor, will interfere with the safety for the&#xD;
        individual subject. Non-sustained or sustained ventricular tachycardia ( greater than or&#xD;
        equal to 3 consecutive ventricular ectopic beats).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>August 25, 2011</study_first_submitted>
  <study_first_submitted_qc>August 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2011</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

